[ad_1]
Takeda Egypt has launched a new drug to treat hemophilia patients in the Egyptian market, believing in its role in providing the latest medicines to the patient, and providing a healthier life for all Egyptians by providing effective and safe medicines, with high quality international specifications.
The conference was attended by a distinguished elite of university professors, the Ministry of Health, health insurance, NGOs, and media professionals. The conference reviewed the company’s efforts to reduce the burdens of patients and provide various treatment options within the framework of Egypt’s Vision 2030, which urges the solidarity of all members of the comprehensive health system in Egypt.
The conference sessions were attended by Dr. Magdy El-Akiabi, Consultant Hematologist and Director of the Shabrawishi International Center for Hemophilia Treatment, Dr. Magda Ali Rakha, Chairman of the Board of Directors of the Friends of Hemorrhagic Patients Association, and Dr. Mohsen Al-Alfi, Professor of Pediatrics at Ain Shams University and President of the Sheryan Al-Ataa Association, President of the Egyptian Society of Pediatric Hematology and Oncology, Dr. Mona Hamdy, Professor of Pediatrics and Hematology at Cairo University and Director of the Hematology and Marrow Transplant Unit at Abu El-Rish University Hospital, Consultant Hematologist at the General Authority for Health Insurance, Dr. Mona El Ghamrawy, Professor of Pediatrics and Hematology at Cairo University, and Dr. Mohamed Talaat Professor of Hematology at Kasr Al-Ainy Medicine, and Dr. Sami Khalil, Director of Takeda Egypt.
Takeda Egypt launches a new drug for hemophilia patients
For his part, Dr. Magdi El-Akiabi, a consultant hematologist and director of the Shabrawichi International Center for Hemophilia Treatment, said that hemophilia is a genetic disease and has varying degrees, explaining that the disease when it affects children leads to bleeding when exposed to any “knock” or injury, especially in the joints, stressing that there are Serious bleeding that affects vital organs in the body, such as the brain, which is exposed to bleeding, or gastrointestinal bleeding, but in general the bleeding is in the muscles or joints, and it must be treated early.
He said, that the current treatments that prevent bleeding have been approved by the World Federation of Hemophilia, to transform the patient from a severe disease to a mild one, noting that hemophilia is one of the rare inherited bleeding disorders, in which blood clotting is disturbed, which may lead to spontaneous bleeding, as well as Bleeding after injuries or surgery, and in some rare cases a person may develop hemophilia later in his life Pregnancy. Females can also carry the gene for the disease without showing any symptoms, but it is passed on to their children.
Dr. Sami Khalil, Director of Affirmation Egypt
He explained, that the genetic fluidity of blood (hemophilia) lives with the patient from birth until the end of life, and the bleeding that the patient suffers may lead to joint damage and motor disability, and the hemophilia child suffers from isolation as a result of fear of bleeding, adding, that home preventive treatment with factor compounds The eighth or ninth clot is the only solution for hemophilia patients to live a better life, but factor VIII concentrates lose their effectiveness when immune bodies are not available in the patient’s body, which is what the new drug relied on.
Dr. Mona Al-Ghamrawy, Professor of Pediatrics and Hematology at Cairo University, stressed that patients with blood flow should be taken care of and noted by doctors, explaining that all hospitals must provide clotting factors, which represents a great challenge, and that the patient is followed up from childhood until he reaches Until adulthood, and its symptoms appear when performing the purification process, explaining that the child bleeds heavily and the surgeon is forced to either perform a second surgical procedure or blood transfusion for the patient, and the disease can be observed in the first months of birth, and sometimes with vaccinations bleeding occurs, and it may occur with stool or urine Or through the mucous membranes of the nose, warning the mother of the child’s exposure to accidents or blows, especially in the brain, abdomen or neck area.
She explained, that many people with hemophilia or those with a family genetic history are asked to take a test for their child after birth, as one third of children diagnosed with hemophilia have a mutation that is not present in family members, and in these cases, the doctor may order a hemophilia test. For a child if he suffers from certain symptoms of hemophilia, and also doctors conduct certain blood tests that show whether the blood clots normally, and in case the blood does not clot naturally, doctors may conduct clotting factor tests, to diagnose the cause of the bleeding disorder, and to find out the type and severity of hemophilia.
Dr. Sami Khalil, Director of Takeda Egypt, said that the company believes in the importance of research and development, explaining that our total global investments amounted to about $4.5 billion annually, and that Emphasis attaches special importance to hemophilia, through specialized training programs for physicians, and support for assistance programs.
He said, “Takeda Egypt seeks to cooperate with all concerned parties in providing medical care and treatment at an appropriate value for the Egyptian patient, as one of the company’s priorities in Egypt is to provide modern and innovative treatments to the patient as soon as possible.”
Dr. Mohamed Talaat, Professor of Hematology at Kasr Al-Ainy Medicine, added that hemophilia patients suffer from walking and life problems, and many of them cannot go to work, explaining that Takeda’s antibody drug prevents the disease from affecting the body’s systems.
For her part, Dr. Magda Ali Rakha, President of the Friends of Hemorrhagic Patients Association, said: The association aims to improve awareness of hemophilia patients, provide them with health services, and solve any problems they encounter. The association plays a major role in cooperation with the Ministry of Health laboratories for early diagnosis of the disease.
Dr. Mohsen Al-Alfi, Professor of Pediatrics and Hematology, stressed that the hemophilia patient must practice his normal life by providing new treatments that do not affect his life.
Dr. Mona Hamdy, Professor of Pediatrics and Hematology at Cairo University, explained that the state is interested in providing treatment through the General Authority for Health Insurance, which provides clotting factors in hospitals.
She said that the whole world provided home treatment for hemophilia patients during the Corona pandemic so that the patient would not be infected with the Corona virus in hospitals, but so far this request has not been approved so that the patient receives his treatment for at least 3 months, explaining that everyone must unite to achieve care. And a better future for hemophilia patients in Egypt.
[ad_2]